XML 61 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Capital and reserves (Tables)
12 Months Ended
Dec. 31, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Schedule of share capital
   
2022
   
2021
 
             
Number of ordinary shares (issued and paid up):
           
Balance at the beginning of the year
   
119,743,188
     
100,000,000
 
Issued in consideration of cash (public offering)
           
15,000,000
 
Exercise of share options (cashless)
   
406,733
     
4,743,188
 
Balance at the end of the year
   
120,149,921
     
119,743,188
 
Schedule of reconciliation of outstanding share options
   
2022
   
2021
 
   
Issuable
shares
   
Weighted
average
exercise
price
   
Issuable
shares
   
Weighted
average
exercise
price
 
Outstanding at the beginning of the period
   
714,322
     
8.04
     
4,990,000
     
1.00
 
Granted during the period
   
2,325,215
     
65.34
     
546,822
     
15.00
 
Exercised during the period
   
(406,733
)
   
0.00
     
(4,822,500
)
   
0.75
 
Fortified during the period
   
(171,374
)
                       
Outstanding at the end of the period
   
2,461,430
     
37.05
     
714,322
     
8.04
 
                                 
Exercisable at the end of the period
                   
167,500
     
0.00
 
Schedule of earnings (loss) per share
   
2022
   
2021
   
2020
 
   
US $ in millions
 
Profit attributable to ordinary shareholders used to calculate basic and diluted earnings per share (US $ in millions)
   
4,619.4
     
4,640.3
     
518.0
 
                         
Number of outstanding shares at the beginning of the period used to calculate basic earnings per share
   
119,910,688
     
100,000,000
     
100,000,000
 
Effect of shares issued
           
13,712,329
         
Effect of share options
   
101,687
     
1,393,175
         
                         
Weighted average number of ordinary shares used to calculate basic earnings per share
   
120,012,375
     
115,105,504
     
100,000,000
 
                         
Effect of share options
   
432,514
     
3,828,219
     
4,530,892
 
                         
Weighted average number of ordinary shares used to calculate diluted earnings per share
   
120,444,889
     
118,933,723
     
104,530,892
 
2018 Grant  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Schedule of share-based payment arrangements
Grant date
 
Instrument terms
 
Number of instruments
 
Vesting Terms
 
Contractual life
June 30, 2018
 
Each option is exercisable into one ordinary share, at the exercise price of the share on the grant date, adjusted to future dividends.
 
4,990,000
 
50%, 25% and 25% of the options are exercisable following a service period of 2 years, 3 years and 4 years, respectively.
 
6 years
Schedule of measurement inputs for fair value of options
Fair value
 
USD 0.362
Share price on grant date
 
USD 1.00
Exercise price
 
USD 1.00
Expected volatility
 
31.9%
Expected life
 
6 years
Expected dividends
 
0%
Risk-free interest rate
 
2.7%
2021 Grant  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Schedule of share-based payment arrangements
Grant date
 
Instrument terms
 
Number of instruments
 
Vesting Terms
 
Contractual life
January 27, 2021
 
Each option is exercisable into one ordinary share, at the exercise price per the offering price of US$ 15.00, adjusted to future dividends.
 
546,822
 
25% of the options shall vest upon the first anniversary of the grant date with the remaining options vesting in equal quarterly portions over the following three years period.
 
5 years
Schedule of measurement inputs for fair value of options
Fair value
 
USD 5.32
Share price on grant date
 
USD 15.00
Exercise price
 
USD 15.00
Expected volatility
 
40.2%
Expected life
 
5 years
Expected dividends
 
0%
Risk-free interest rate
 
0.46%
2022 Grant  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Schedule of share-based payment arrangements
Granted in
 
Number of instruments
 
Instrument terms
 
Vesting terms
 
Contractual life
March 2022
 
 
1,727,443
 
Each option is exercisable into one ordinary share on a cash-less basis.
 
These options shall vest upon the first, second, third and fourth anniversary, in four equal instalments of 25% each.
 
5 years

May 2022

  490,662            
                 

August 2022

  107,110            
Schedule of measurement inputs for fair value of options
Granted in
 
March 2022
May 2022
August 2022
Fair Value
 
USD 29.72
USD 26.30
USD 25.07
Share price on grant date
 
USD 68.94
USD 55.63
USD 51.86
Exercise price
 
USD 68.37
USD 51.37
USD 47.78
Expected volatility
 
47.3%
48.4%
48.9%
Expected life
 
5 years
4.9 years
5 years
Expected dividends
 
0%
0%
0%
Risk-free interest rate
 
1.7%
3.0%
3.0%